Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 108

1.

Topical tenofovir, a microbicide effective against HIV, inhibits herpes simplex virus-2 replication.

Andrei G, Lisco A, Vanpouille C, Introini A, Balestra E, van den Oord J, Cihlar T, Perno CF, Snoeck R, Margolis L, Balzarini J.

Cell Host Microbe. 2011 Oct 20;10(4):379-89. doi: 10.1016/j.chom.2011.08.015.

PMID:
22018238
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Antiviral and immunological effects of tenofovir microbicide in vaginal herpes simplex virus 2 infection.

Vibholm L, Reinert LS, Søgaard OS, Paludan SR, Østergaard L, Tolstrup M, Melchjorsen J.

AIDS Res Hum Retroviruses. 2012 Nov;28(11):1404-11. doi: 10.1089/AID.2012.0078. Epub 2012 Sep 25.

PMID:
22867119
[PubMed - indexed for MEDLINE]
3.

Antiviral activity of genital tract secretions after oral or topical tenofovir pre-exposure prophylaxis for HIV-1.

Herold BC, Dezzutti CS, Richardson BA, Marrazzo J, Mesquita PM, Carpenter C, Huber A, Louissaint N, Marzinke MA, Hillier SL, Hendrix CW.

J Acquir Immune Defic Syndr. 2014 May 1;66(1):65-73. doi: 10.1097/QAI.0000000000000110.

PMID:
24457633
[PubMed - indexed for MEDLINE]
4.

A multi-targeted drug candidate with dual anti-HIV and anti-HSV activity.

Balzarini J, Andrei G, Balestra E, Huskens D, Vanpouille C, Introini A, Zicari S, Liekens S, Snoeck R, Holý A, Perno CF, Margolis L, Schols D.

PLoS Pathog. 2013;9(7):e1003456. doi: 10.1371/journal.ppat.1003456. Epub 2013 Jul 25.

PMID:
23935482
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Susceptibility to genital herpes as a biomarker predictive of increased HIV risk: expansion of a murine model of microbicide safety.

Wilson SS, Cheshenko N, Fakioglu E, Mesquita PM, Keller MJ, Herold BC.

Antivir Ther. 2009;14(8):1113-24. doi: 10.3851/IMP1463.

PMID:
20032541
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Prevention of SIV rectal transmission and priming of T cell responses in macaques after local pre-exposure application of tenofovir gel.

Cranage M, Sharpe S, Herrera C, Cope A, Dennis M, Berry N, Ham C, Heeney J, Rezk N, Kashuba A, Anton P, McGowan I, Shattock R.

PLoS Med. 2008 Aug 5;5(8):e157; discussion e157. doi: 10.1371/journal.pmed.0050157.

PMID:
18684007
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Simultaneous delivery of tenofovir and acyclovir via an intravaginal ring.

Moss JA, Malone AM, Smith TJ, Kennedy S, Kopin E, Nguyen C, Gilman J, Butkyavichene I, Vincent KL, Motamedi M, Friend DR, Clark MR, Baum MM.

Antimicrob Agents Chemother. 2012 Feb;56(2):875-82. doi: 10.1128/AAC.05662-11. Epub 2011 Nov 28.

PMID:
22123689
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Zinc acetate/carrageenan gels exhibit potent activity in vivo against high-dose herpes simplex virus 2 vaginal and rectal challenge.

Fernández-Romero JA, Abraham CJ, Rodriguez A, Kizima L, Jean-Pierre N, Menon R, Begay O, Seidor S, Ford BE, Gil PI, Peters J, Katz D, Robbiani M, Zydowsky TM.

Antimicrob Agents Chemother. 2012 Jan;56(1):358-68. doi: 10.1128/AAC.05461-11. Epub 2011 Nov 7.

PMID:
22064530
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

One percent tenofovir applied topically to humanized BLT mice and used according to the CAPRISA 004 experimental design demonstrates partial protection from vaginal HIV infection, validating the BLT model for evaluation of new microbicide candidates.

Denton PW, Othieno F, Martinez-Torres F, Zou W, Krisko JF, Fleming E, Zein S, Powell DA, Wahl A, Kwak YT, Welch BD, Kay MS, Payne DA, Gallay P, Appella E, Estes JD, Lu M, Garcia JV.

J Virol. 2011 Aug;85(15):7582-93. doi: 10.1128/JVI.00537-11. Epub 2011 May 18.

PMID:
21593172
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Drug delivery in multiple indication (multipurpose) prevention technologies: systems to prevent HIV-1 transmission and unintended pregnancies or HSV-2 transmission.

Friend DR.

Expert Opin Drug Deliv. 2012 Apr;9(4):417-27. doi: 10.1517/17425247.2012.668183. Epub 2012 Mar 2. Review.

PMID:
22385316
[PubMed - indexed for MEDLINE]
11.

A combination microbicide gel protects macaques against vaginal simian human immunodeficiency virus-reverse transcriptase infection, but only partially reduces herpes simplex virus-2 infection after a single high-dose cochallenge.

Hsu M, Aravantinou M, Menon R, Seidor S, Goldman D, Kenney J, Derby N, Gettie A, Blanchard J, Piatak M Jr, Lifson JD, Fernández-Romero JA, Zydowsky TM, Robbiani M.

AIDS Res Hum Retroviruses. 2014 Feb;30(2):174-83. doi: 10.1089/AID.2013.0165. Epub 2013 Nov 22.

PMID:
24117013
[PubMed - indexed for MEDLINE]
Free PMC Article
12.
13.

Intravaginal ring delivery of tenofovir disoproxil fumarate for prevention of HIV and herpes simplex virus infection.

Mesquita PM, Rastogi R, Segarra TJ, Teller RS, Torres NM, Huber AM, Kiser PF, Herold BC.

J Antimicrob Chemother. 2012 Jul;67(7):1730-8. doi: 10.1093/jac/dks097. Epub 2012 Mar 30.

PMID:
22467632
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

In vitro and ex vivo testing of tenofovir shows it is effective as an HIV-1 microbicide.

Rohan LC, Moncla BJ, Kunjara Na Ayudhya RP, Cost M, Huang Y, Gai F, Billitto N, Lynam JD, Pryke K, Graebing P, Hopkins N, Rooney JF, Friend D, Dezzutti CS.

PLoS One. 2010 Feb 19;5(2):e9310. doi: 10.1371/journal.pone.0009310.

PMID:
20174579
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Natural killer cell function in women at high risk for HIV acquisition: insights from a microbicide trial.

Naranbhai V, Altfeld M, Abdool Karim Q, Ndung'u T, Abdool Karim SS, Carr WH; Centre for the AIDS Programme of Research in South Africa (CAPRISA) Tenofovir gel Research for AIDS Prevention Science (TRAPS) Team.

AIDS. 2012 Sep 10;26(14):1745-53.

PMID:
22781225
[PubMed - indexed for MEDLINE]
16.

Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals.

Burrel S, Deback C, Agut H, Boutolleau D.

Antimicrob Agents Chemother. 2010 Nov;54(11):4833-42. doi: 10.1128/AAC.00669-10. Epub 2010 Aug 23.

PMID:
20733037
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Reformulated tenofovir gel for use as a dual compartment microbicide.

Dezzutti CS, Rohan LC, Wang L, Uranker K, Shetler C, Cost M, Lynam JD, Friend D.

J Antimicrob Chemother. 2012 Sep;67(9):2139-42. doi: 10.1093/jac/dks173. Epub 2012 May 11.

PMID:
22581908
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

DNA polymerase mutations in drug-resistant herpes simplex virus mutants determine in vivo neurovirulence and drug-enzyme interactions.

Andrei G, Fiten P, Froeyen M, De Clercq E, Opdenakker G, Snoeck R.

Antivir Ther. 2007;12(5):719-32.

PMID:
17713155
[PubMed - indexed for MEDLINE]
19.

A randomized trial to assess anti-HIV activity in female genital tract secretions and soluble mucosal immunity following application of 1% tenofovir gel.

Keller MJ, Madan RP, Torres NM, Fazzari MJ, Cho S, Kalyoussef S, Shust G, Mesquita PM, Louissaint N, Chen J, Cohen HW, Diament EC, Lee AC, Soto-Torres L, Hendrix CW, Herold BC.

PLoS One. 2011 Jan 25;6(1):e16475. doi: 10.1371/journal.pone.0016475.

PMID:
21283552
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Successful treatment of progressive mucocutaneous infection due to acyclovir- and foscarnet-resistant herpes simplex virus with (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC).

Snoeck R, Andrei G, Gérard M, Silverman A, Hedderman A, Balzarini J, Sadzot-Delvaux C, Tricot G, Clumeck N, De Clercq E.

Clin Infect Dis. 1994 Apr;18(4):570-8.

PMID:
8038312
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk